Last update : 05/06/2021 | Version : 1 | ID : 73876
General | |
Identification | |
Detailed name | Study on the impact of Covid-19 on use, practices and health among regular cannabis users |
Sign or acronym | CANNAVID |
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation | CNIL 2217595 |
General Aspects | |
Medical area |
Infectious diseases Psychology and psychiatry |
Study in connection with Covid-19 |
Yes |
Pathology (details) | addiction, inflammatory diseases, psychiatric disorders, cardiac or vascular disease, obesity or other metabolic disease, respiratory diseases, infectious diseases, cancer |
Health determinants |
Addictions Healthcare system and access to health care services Lifestyle and behavior Occupation Social and psychosocial factors |
Keywords | Cannabis and other illicit substances, Covid-19, mental health, pain, lockdown |
Scientific investigator(s) (Contact) | |
Name of the director | Roux |
Surname | Perrine |
Address | Sciences Economiques et Sociales de la Santé et Traitement de l'Information Médicale<br>Faculté de médecine<br>27 bd Jean Moulin<br>13005 Marseille |
Phone | +33(0)4 13 73 22 78 |
perrine.roux@inserm.fr | |
Unit | UMR 1252 SESSTIM |
Organization | Inserm |
Collaborations | |
Participation in projects, networks and consortia |
No |
Funding | |
Funding status |
Mixed |
Details | no funding for this study |
Governance of the database | |
Sponsor(s) or organisation(s) responsible | Bus 31/32 Association (CSAPA, CAARUD) |
Organisation status |
Private |
Presence of scientific or steering committees |
Yes |
Labelling and database evaluation | internal audit |
Additional contact | |
Name of the contact | Lebrun Gadelius |
Surname | Maela |
Address | Bus 31/32<br>4 avenue Rostand <br>13003 Marseille<br> |
Phone | 04 95 04 56 06 |
maela.lebrun@bus3132.org | |
Organization | Bus 31/32 |
Main features | |
Type of database | |
Type of database |
Study databases |
Study databases (details) |
Repeated cross-sectional studies (except case control studies) |
Database recruitment is is made on the basis of: |
Another treatment or procedure |
Database recruitment is carried out as part of an interventional study |
No |
Additional information regarding sample selection. | Promotion of the study via different websites aimed at cannabis users (patient or harm reduction associations, social network). |
Database objective | |
Main objective | Evaluate the impact of the different lockdowns on cannabis use practices among daily users, psychoactive substance use and the onset of related symptoms (withdrawal, pain, sleep disorders, anxiety, depression). |
Inclusion criteria |
Daily cannabis users or individuals having taken part in the previous CANNAVID series for questionnaires completed from the second lockdown;
Aged over 18 years; Able to understand French; Residing in France; Agreeing to take part in the study and having expressed their non-objection. |
Population type | |
Age |
Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more) |
Population covered |
General population |
Pathology | |
Gender |
Male Woman Other |
Geography area |
National |
Detail of the geography area | France |
Data collection | |
Dates | |
Date of first collection (YYYY or MM/YYYY) | 2020 |
Date of last collection (YYYY or MM/YYYY) | 2020 |
Size of the database | |
Size of the database (number of individuals) |
[1000-10 000[ individuals |
Details of the number of individuals | First lockdown: 4,019 participants |
Data | |
Database activity |
Current data collection |
Type of data collected |
Declarative data |
Declarative data (detail) |
Internet self-questionnaire |
Details of collected declarative data | Sociodemographic characteristics (age, gender, level of education, accommodation, parenthood), before and during the lockdown (accommodation, professional activity, recourse to a food bank); psychoactive substance use (use, supply, storage, quantities used, adverse reactions, withdrawal symptoms, substance analyses, penalties due to cannabis use) before and during the lockdown, changes in use between lockdowns; health status and practices (chronic disorders, treatments, symptoms of Covid-19, overdoses, medical appointments, Hospital Anxiety and Depression scale before and during the lockdown. |
Presence of a biobank |
No |
Health parameters studied |
Health event/morbidity Quality of life/health perception |
Quality of life/perceived health (detail) | state of health before and during the lockdown |
Procedures | |
Data collection method | Data collection via the internet |
Classifications used | Hospital Anxiety and Depression scale, withdrawal symptoms (American Psychiatric Association 2013), ICD-10 |
Quality procedure(s) used | methodology centre specialised in epidemiological studies |
Participant monitoring |
Yes |
Details on monitoring of participants | please state whether the participant took part in the first questionnaire series |
Followed pathology | F10-F19 - Mental and behavioural disorders due to psychoactive substance use |
Links to administrative sources |
No |
Promotion and access | |
Promotion | |
Link to the document | https://www.cairn.info/revue-psychotropes-2020-2-page-141.htm |
Description | CANNAVID survey: Changes in cannabis use among daily users during the Covid-19 pandemic |
Other information | Preliminary results available on: https://infogram.com/cannavid-resultats-preliminaires-1hzj4onmnjlo2pw?live |
Access | |
Dedicated website | https://cannavid.limequery.com/439624?lang=fr |
Presence of document that lists variables and coding procedures |
Yes |
Terms of data access (charter for data provision, format of data, availability delay) | Methods for accessing the database are in the process of being defined |
Access to aggregated data |
Access on specific project only |
Access to individual data |
Access on specific project only |
Partners - FAQ - Contact - Site map - Legal notices - Administration - Updated on December 15 2020 - Version 4.10.05